AMENDMENTS TO THE CLAIMS

1. (Original) A compound of general formula (I)



I

wherein

R^1, R^2, R^3 and R^4 are independently hydrogen, halo, C_1-C_6 alkyl, -O(C_1-C_6 alkyl), -CON(R^9)$_2$, -SOR^9, -SO_2R^9, -SO_2N(R^9)$_2$, -N(R^9)$_2$, -NR^9COR^9, -CO_2R^9, -COR^9, -SR^9, -OH, -NO_2 or -CN;

each R^9 is independently hydrogen or C_1-C_6 alkyl;

R^5 and R^6 are each independently hydrogen, or C_1-C_6 alkyl or together with the carbon atom to which they are attached form a C_3-C_7 cycloalkyl group;

R^7 is hydrogen or C_1-C_6 alkyl

n is 1 or 2;

X is a bond or, when n is 2, X may also be a NR^9 group;

wherein R^9 is as defined above;

when X is a bond R^8 is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, biphenyl or a 9-14 membered bicyclic or tricyclic heteroaryl group;

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

when X is a NR^9 group R^8 may additionally be phenyl, naphthyl or a 5-7 membered heteroaromatic ring; and

the R^8 group is optionally substituted with one or more substituents selected from halo, C_1-C_6 alkyl, -O(C_1-C_6)alkyl, aryl, -O-aryl, heteroaryl, -O-heteroaryl, -CON(R^9)$_2$, -SOR^9, -SO_2R^9, $SO_2N(R^9)_2$, -N(R^9)$_2$, -NR^9COR^9, -CO_2R^9, -COR^9, -SR^9, -OH, -NO_2 or -CN;

wherein R^9 is as defined above;

or a pharmaceutically acceptable salt, hydrate, solvate, complex or prodrug thereof.

2-30. (Canceled)

31. (New) A compound as claimed in claim 1 wherein, independently or in any combination:

R^1 is halo or hydrogen;

R^2 is halo or hydrogen;

R^3 is halo or hydrogen;

R^4 is halo or hydrogen.

32. (New) A compound as claimed in claim 1 wherein R^1, R^3 and R^4 are hydrogen and R^2 is halo.

33. (New) A compound as claimed in claim 32 wherein R^2 is fluoro.

34. (New) A compound as claimed in claim 1 wherein R^5 and R^6 are each independently hydrogen or C_1-C_4 alkyl.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

35. (New) A compound as claimed in claim 34 wherein at least one of R^5 and R^6 are hydrogen.

36. (New) A compound as claimed in claim 35 wherein both R^5 and R^6 are hydrogen.

37. (New) A compound as claimed in claim 1 wherein R^7 is H or C_1-C_6 alkyl.

38. (New) A compound as claimed in claim 37 wherein R^7 is methyl.

39. (New) A compound as claimed in claim 1 wherein n is 2.

40. (New) A compound as claimed in claim 1 wherein X is a bond and R^8 is C_1-C_6 alkyl, biphenyl or a bicyclic heteroaryl group, any of which may be substituted with halogen, phenyl, $-CO_2R^9$ $CON(R^9)_2$ or $-SO_2R^9$, where R^9 is as defined in claim 1.

41. (New) A compound as claimed in claim 41 wherein R^8 is selected from the group consisting of a C_1-C_4 alkyl, biphenyl, and a bicyclic heteroaryl group, any of which may be substituted with phenyl, $-CO_2R^9$ $CON(R^9)_2$ or $-SO_2R^9$, where R^9 is H or C_1-C_4 alkyl.

42. (New) A compound as claimed in claim 1 wherein X is NR^9, R^9 is H or methyl and R^8 is selected from the group consisting of:

phenyl optionally substituted with one or more halo, C_1-C_6 alkyl or $-O(C_1$-C_6 alkyl) groups;

C_1-C_6 alkyl, optionally substituted with aryl; and

heteroaryl.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

43. (New) A compound as claimed in claim 42, wherein R^8 is selected from the group consisting of phenyl, benzyl or pyridyl, any of which may optionally be substituted with one or more halo, methyl or methoxy groups.

44. (New) A compound of general formula (II):



II

wherein R^1, R^2, R^3, R^4, R^5 , R^6, n, X, R^7 and R^8 are as defined for general formula (I); R^{10} is C_1-C_6 alkyl, aryl, $(CH_2)_mOC(=O)C_1$-C_6alkyl, $(CH_2)_mN(R^{11})_2$, $CH((CH_2)_mO(C=O)R^{12})_2$;

m is 1 or 2;

R^{11} is hydrogen or methyl;

R^{12} is C_1-C_{18} alkyl.

45. (New) A compound as claimed in claim 15 wherein, independently or in any combination:

R^1 is halo or hydrogen;

R^2 is halo or hydrogen;

R^3 is halo or hydrogen;

R^4 is halo or hydrogen.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

46. (New) A compound as claimed in claim 44 wherein R^1, R^3 and R^4 are hydrogen and R^2 is halo.

47. (New) A compound as claimed in claim 46 wherein R^2 is fluoro.

48. (New) A compound as claimed in claim 44 wherein R^5 and R^6 are each independently hydrogen or C_1-C_4 alkyl.

49. (New) A compound as claimed in claim 48 wherein at least one of R^5 and R^6 are hydrogen.

50. (New) A compound as claimed in claim 38 wherein both R^5 and R^6 are hydrogen.

51. (New) A compound as claimed in claim 44 wherein R^7 is H or C_1-C_6 alkyl.

52. (New) A compound as claimed in claim 51 wherein R^7 is methyl.

53. (New) A compound as claimed in claim 44 wherein n is 2.

54. (New) A compound as claimed in claim 44 wherein X is a bond and R^8 is C_1-C_6 alkyl, biphenyl or a bicyclic heteroaryl group, any of which may be substituted with halogen, phenyl, $-CO_2R^9$ $CON(R^9)_2$ or $-SO_2R^9$, where R^9 is as defined in claim 1.

55. (New) A compound as claimed in claim 54 wherein R^8 is selected from the group consisting of a C_1-C_4 alkyl, biphenyl, a bicyclic heteroaryl group and a 5-7 membered heterocyclic ring, any of which may be substituted with phenyl, $-CO_2R^9$ $CON(R^9)_2$ or $-SO_2R^9$, where R^9 is H or C_1-C_4 alkyl.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

56. (New) A compound as claimed in claim 44 wherein X is NR^9, R^9 is H or methyl and R^8 is selected from the group consisting of:

phenyl optionally substituted with one or more halo, C_1-C_6 alkyl or -O(C_1-C_6 alkyl) groups;

C_1-C_6 alkyl, optionally substituted with aryl; and

heteroaryl.

57. (New) A compound as claimed in claim 56, wherein R^8 is selected from the group consisting of phenyl, benzyl or pyridyl, any of which may optionally be substituted with one or more halo, methyl or methoxy groups.

58. (New) A compound selected from the group consisting of:

[3-(Butane-1-sulfonyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid

3-(Biphenyl-4-sulfonyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid

(3-Carboxymethanesulfonyl-5-fluoro-2-methyl-indol-1-yl)-acetic acid

(3-Carbamoylmethanesulfonyl-5-fluoro-2-methyl-indol-1-yl)-acetic acid

[5-Fluoro-3-(2-methanesulfonyl-ethanesulfonyl)-2-methyl-indol-1-yl]-acetic acid

[3-(Benzothiazole-2-sulfonyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid

[3-(Benzothiazole-2-sulfinyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid

[5-Fluoro-2-methyl-3-(quinoline-2-sulfonyl)-indol-1-yl]-acetic acid

[5-Fluoro-2-methyl-3-(quinolin-8-ylsulfonyl)-indol-1-yl]-acetic acid

(5-Fluoro-2-methyl-3-phenylmethanesulfonyl-1H-indol-1-yl)-acetic acid

[3-(4-Chloro-phenylsulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid

[3-(3-Chloro-phenylsulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid

[3-(4-Fluoro-phenylsulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

[3-(2-Chloro-phenylsulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid

(3-Benzylsulfamoyl-5-fluoro-2-methyl-indol-1-yl)-acetic acid

[5-Fluoro-3-(2-methoxy-phenylsulfamoyl)-2-methyl-indol-1-yl]-acetic acid

[5-Fluoro-3-(4-methoxy-phenylsulfamoyl)-2-methyl-indol-1-yl]-acetic acid

(5-Fluoro-2-methyl-3-phenylsulfamoyl-indol-1-yl)-acetic acid

[3-(3,4-Dichloro-benzylsulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-aceticacid

[5-Fluoro-3-(3-methoxy-phenylsulfamoyl)-2-methyl-indol-1-yl]-acetic acid

(5-Fluoro-2-methyl-3-*m*-tolylsulfamoyl-indol-1-yl)-acetic acid

(5-Fluoro-2-methyl-3-p-tolylsulfamoyl-indol-1-yl)-acetic acid

[3-(4-Chloro-benzylsulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid

[3-(Benzyl-methyl-sulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid

[5-Fluoro-2-methyl-3-(pyridin-3-ylsulfamoyl)-indol-1-yl]-acetic acid;

and the C_1-C_6 alkyl, aryl, $(CH_2)_mOC(=O)C_1$-C_6alkyl, $(CH_2)_mN(R^{11})_2$, $CH((CH_2)_mO(C=O)R^{12})_2$ esters of any of the above; wherein

m is 1 or 2;

R^{11} is hydrogen or methyl;

R^{12} is C_1-C_{18} alkyl.

59. (New) A process for the preparation of a compound of general formula (I) as claimed claim 1 and wherein n is 1 or 2 and X is a bond, the process comprising treating a compound of general formula (Ia), which is a compound of general formula (I) wherein n is 0 and X is a bond, by oxidation with a suitable oxidising agent.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

60. (New) A process for the preparation of a compound of general formula (I) as claimed in claim 1, the process comprising reacting a compound of general formula (II) as defined in claim 44 and wherein R^{10} is C_1-C_6 alkyl with a base.

61. (New) A method for the treatment of a disease or condition mediated by the action of PGD_2 at the CRTH2 receptor, the method comprising administering to a patient in need of such treatment a compound as claimed in claim 1 or a compound as claimed in claim 44.

62. (New) The method of claim 61, further comprising administering to the patient one or more additional active agents useful in the treatment of diseases and conditions mediated by PGD_2 at the CRTH2 receptor.

63. (New) The method of claim 62 wherein the additional active agents are selected from the group consisting of β2 agonists, corticosteroids, antihistamines, leukotriene antagonists, anti-IgE antibody therapies, anti-infectives, anti-fungals, immunosuppressants, other antagonists of PGD_2 acting at other receptors, inhibitors of phoshodiesterase type 4, drugs that modulate cytokine production, drugs that modulate the activity of Th2 cytokines IL-4 and IL-5, PPAR-γ agonists and 5-lipoxygenase.

64. (New) The method of claim 63, wherein the additional active agents are selected from the group consisting of salmeterol, fluticasone, loratidine, montelukast, omalizumab, fusidic acid, clotrimazole, tacrolimus, pimecrolimus, DP antagonists, cilonilast, inhibitors of TNFα converting enzyme (TACE), blocking monoclonal antibodies, soluble receptors, rosiglitazone and zileuton.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

65. (New) A method for the treatment of a disease or condition selected from the group consisting of allergic asthma, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity (including contact dermatitis), conjunctivitis, especially allergic conjunctivitis, eosinophilic bronchitis, food allergies, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis and Crohn's disease, mastocytosis, autoimmune diseases such as hyper IgE syndrome and systemic lupus erythematus, psoriasis, acne, multiple sclerosis, allograft rejection, reperfusion injury and chronic obstructive pulmonary disease; or rheumatoid arthritis, psoriatic arthritis and osteoarthritis, the method comprising administering to a patient in need of such treatment a compound as claimed in claim 1 or a compound as claimed in claim 44.

66. (New) The method of claim 65, further comprising administering to the patient one or more additional active agents useful in the treatment of diseases and conditions mediated by PGD_2 at the CRTH2 receptor.

67. (New) The method of claim 66 wherein the additional active agents are selected from the group consisting of β2 agonists, corticosteroids, antihistamines, leukotriene antagonists, anti-IgE antibody therapies, anti-infectives, anti-fungals, immunosuppressants, other antagonists of PGD_2 acting at other receptors, inhibitors of phoshodiesterase type 4, drugs that modulate cytokine production, drugs that modulate the activity of Th2 cytokines IL-4 and IL-5, PPAR-γ agonists and 5-lipoxygenase.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

68. (New) The method of claim 67, wherein the additional active agents are selected from the group consisting of salmeterol, fluticasone, loratidine, montelukast, omalizumab, fusidic acid, clotrimazole, tacrolimus, pimecrolimus, DP antagonists, cilonilast, inhibitors of TNFα converting enzyme (TACE), blocking monoclonal antibodies, soluble receptors, rosiglitazone and zileuton.

69. (New) A pharmaceutical composition comprising a compound as claimed in claim 1 together with a pharmaceutical excipient or carrier.

70. (New) A composition as claimed in claim 69 formulated for oral, rectal, nasal, bronchial (inhaled), topical (including eye drops, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration.

71. (New) A composition as claimed in claim 70 formulated for oral, nasal, bronchial or topical administration.

72. (New) A composition as claimed in claim 69 containing one or more additional active agents useful in the treatment of diseases and conditions mediated by PGD_2 at the CRTH2 receptor.

73. (New) A composition as claimed in claim 72, wherein the additional active agents are selected from the group consisting of β2 agonists, corticosteroids, antihistamines, leukotriene antagonists, anti-IgE antibody therapies, anti-infectives, anti-fungals, immunosuppressants, other antagonists of PGD_2 acting at other receptors, inhibitors of phoshodiesterase type 4, drugs that modulate cytokine production, drugs that modulate the activity of Th2 cytokines IL-4 and IL-5, PPAR-γ agonists and 5-lipoxygenase.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

74. (New) A composition as claimed in claim 73, wherein the additional active agents are selected from the group consisting of salmeterol, fluticasone, loratidine, montelukast, omalizumab, fusidic acid, clotrimazole, tacrolimus, pimecrolimus, DP antagonists, cilonilast, inhibitors of TNFα converting enzyme (TACE), blocking monoclonal antibodies, soluble receptors, rosiglitazone and zileuton.

75. (New) A pharmaceutical composition comprising a compound as claimed in claim 44 together with a pharmaceutical excipient or carrier.

76. (New) A composition as claimed in claim 75 formulated for oral, rectal, nasal, bronchial (inhaled), topical (including eye drops, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration.

77. (New) A composition as claimed in claim 76 formulated for oral, nasal, bronchial or topical administration.

78. (New) A composition as claimed in claim 46 containing one or more additional active agents useful in the treatment of diseases and conditions mediated by PGD_2 at the CRTH2 receptor.

79. (New) A composition as claimed in claim 78, wherein the additional active agents are selected from the group consisting of β2 agonists, corticosteroids, antihistamines, leukotriene antagonists, anti-IgE antibody therapies, anti-infectives, anti-fungals, immunosuppressants, other antagonists of PGD_2 acting at other receptors, inhibitors of phoshodiesterase type 4, drugs that modulate cytokine production, drugs that modulate the activity of Th2 cytokines IL-4 and IL-5, PPAR-γ agonists and 5-lipoxygenase.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

80. (New) A composition as claimed in claim 79, wherein the additional active agents are selected from the group consisting of salmeterol, fluticasone, loratidine, montelukast, omalizumab, fusidic acid, clotrimazole, tacrolimus, pimecrolimus, DP antagonists, cilonilast, inhibitors of TNFα converting enzyme (TACE), blocking monoclonal antibodies, soluble receptors, rosiglitazone and zileuton.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100